vTv Therapeutics Inc. Income Statement
VTVT|11 years of annual SEC 10-K data (FY2015-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 11 fiscal years. All figures from audited SEC 10-K filings.
vTv Therapeutics Inc. reported $0 in revenue and $20M in net loss for FY2025. Revenue has grown at a 8.4% compound annual rate over the past 9 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $2.0M | $4.0M | $6.4M | $2.8M | $12.4M | $291.0K | $634.0K | $519.0K | $1.5M | $976.0K |
| SG&A Expense | $11.9M | $12.2M | $12.3M | $7.3M | $8.5M | $9.2M | $11.3M | $9.9M | $9.1M | $11.7M | $11.4M |
| R&D Expense | $13.6M | $12.4M | $13.3M | $11.0M | $15.1M | $23.0M | $39.6M | $45.0M | $27.2M | $17.4M | $22.3M |
| Operating Income | -$25.5M | -$22.5M | -$21.7M | -$11.9M | -$20.9M | -$19.8M | -$50.7M | -$55.0M | -$38.1M | -$28.9M | -$35.8M |
| Interest Expense | - | - | $12.0K | $692.0K | $1.8M | $3.3M | $3.1M | $398.0K | $108.0K | $286.0K | $476.0K |
| Income Tax | $0 | $200.0K | $115.0K | $0 | $100.0K | $200.0K | $800.0K | $0 | $0 | $0 | $0 |
| Net Income | -$20.3M | -$19.2M | -$13.0M | -$8.5M | -$13.0M | -$7.9M | -$16.1M | -$16.4M | -$27.5M | -$36.1M | -$48.2M |
| Operating Margin | - | -1116.9% | -540.9% | -184.8% | -755.9% | -159.4% | -17416.5% | -8678.2% | -7349.1% | -1865.5% | -3671.4% |
| Profit Margin | - | -949.6% | -324.3% | -132.5% | -471.9% | -63.6% | -5547.8% | -2579.2% | -5298.3% | -2330.6% | -4938.8% |